Literature DB >> 12715170

Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.

E Fokkema1, E G E De Vries, H J M Groen, C Meijer, W Timens.   

Abstract

PURPOSE: In order to understand the apoptosis pathway in tumor cells, differences in cell morphology and expression of apoptosis-related proteins induced by radiation and/or chemotherapy, were investigated in a rat double tumor model comparing cisplatin-sensitive and -resistant human small cell lung cancer tumors.
METHODS: The cisplatin-sensitive human small cell lung cancer cell line (GLC4) and its cisplatin-resistant subline (GLC4-CDDP) were each injected subcutaneously in a different hind limb of the rat. After 15-17 days, radiation (10 Gy), carboplatin (25 mg/kg, intraperitoneal), combined treatment, or no treatment was administered. In combined treatment, carboplatin was administered 24 h before radiation. Tumors were removed and fixed 72 h after carboplatin or 48 h after radiation. Paraffin-embedded slides were stained with hematoxylin/eosin for morphology. Expression of the apoptosis-related proteins p53, p21, Rb, bcl-2, bax, c-myc, Fas and Fas-L was assessed immunohistochemically.
RESULTS: In the GLC4 tumor, carboplatin treatment increased tumor cell size, tumor cell size heterogeneity, and number of apoptotic tumor cells. After radiation and combined treatment, these changes were more pronounced and multinuclear giant cells were observed. In GLC4-CDDP tumors, minimal changes were detected after carboplatin. Following radiation slight increases in tumor cell size, tumor cell size heterogeneity and number of apoptotic tumor cells were observed. No multinuclear giant cells were seen. After combined treatment, GLC4-CDDP showed cellular changes comparable to those in GLC4 cells after radiation or combined treatment, but no giant cells were observed. Untreated, both tumors were equally positive for p53, bax, Fas, Fas-L, c-myc and negative for Rb. Contrary to GLC4, untreated GLC4-CDDP tumors showed no p21 and bcl-2 expression. After combined treatment, an increase in number of bcl-2 positive cells was found in GLC4-CDDP tumors. No p21 was induced in GLC4-CDDP by any treatment modality. In GLC4 tumors, p21 was induced by radiation alone. No further changes in protein expression were induced by any treatment in GLC4 tumors.
CONCLUSION: Following therapy, morphological changes in cell size and cell size heterogeneity were more pronounced in GLC4 than in GLC4-CDDP tumors. However, morphological changes in GLC4-CCDP tumors after treatment indicate that carboplatin plus radiotherapy may be effective also in cisplatin resistant tumor cells. An increase in p21 in GLC4 after radiation might facilitate apoptosis. The increase in number of Bcl-2 positive cells after combined treatment and the consistently negative p21 status after any treatment in GLC4-CDDP may protect these tumor cells from apoptosis as a part of their resistance mechanism to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715170     DOI: 10.1007/s00428-003-0763-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

2.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

3.  Persistent decrease in viability as a function of X irradiation of human bladder carcinoma cells in G1 or S phase.

Authors:  E A Leonhardt; M Trinh; H B Forrester; W C Dewey
Journal:  Radiat Res       Date:  1998-04       Impact factor: 2.841

Review 4.  Dysregulation of apoptosis in cancer.

Authors:  J C Reed
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism.

Authors:  B G Wouters; A J Giaccia; N C Denko; J M Brown
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 6.  Radiation-induced apoptosis: relevance to radiotherapy.

Authors:  W C Dewey; C C Ling; R E Meyn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-11-01       Impact factor: 7.038

7.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

Authors:  C Meijer; N H Mulder; H Timmer-Bosscha; W J Sluiter; G J Meersma; E G de Vries
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

8.  Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.

Authors:  G Los; E M Verdegaal; P H Mutsaers; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Authors:  C Meijer; N H Mulder; G A Hospers; D R Uges; E G de Vries
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.

Authors:  H J Groen; S Sleijfer; C Meijer; H H Kampinga; A W Konings; E G De Vries; N H Mulder
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more
  2 in total

1.  A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Authors:  Paul K Paik; Charles M Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William Travis; Leonard James; Michelle S Ginsberg; Rosalyn Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-18       Impact factor: 3.333

2.  The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments.

Authors:  Hong-Bin Sun; He-Yuan Wang; Bing Wu; Zhong-Feng Wang; Li-Zhe Wang; Fu-Qiang Li; Jun-Duo Wu; Le-Ning Zhang
Journal:  Oncol Lett       Date:  2019-10-29       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.